A new clinical practice update outlines a stepwise approach to diagnosing and managing refractory constipation before ...

Piper upgraded Ardelyx to ‘Overweight’ and lifted its price target to $16 after sharply higher 2026 guidance. ・The company ...

Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1 IBSRELA achieved $274 million in revenue in 2025, representing 73% growth vs. 20241 ...

Ardelyx shares rose after the company said it expects sales from its drug Ibsrela to hit $1 billion within three years. The stock climbed 16.2% to $6.77 Thursday. Shares are up 16% this year. The ...

Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1 IBSRELA achieved $274 million in revenue in 2025, representing 73% growth vs. 20241 ...

Shilpa Medicare targets US approval of 5-HT3 receptor antiemetic for chemotherapy-induced nausea and vomiting: Our Bureau, Bengaluru Friday, January 9, 2026, 12:15 Hrs [IST] Shilp ...

Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary ...

Last year, gut health was centre-stage and, in the opening days of 2026, the UK has seen a clutch of major retailers roll out ...

Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- ...

The human body already has an efficient, round-the-clock detoxification system driven mainly by the liver, kidneys, lungs, ...

For 2026, Ardelyx expects IBSRELA revenue to reach between $410 and $430 million, representing at least 50% growth over 2025. The company projects IBSRELA will achieve $1 billion in revenue by 2029, ...

Agreement expands Madrigal's pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra- (resmetirom) for poten ...